S100A6, Calumenin and Cytohesin 2 as Biomarkers for Cutaneous Involvement in Systemic Sclerosis Patients: A Case Control Study.
S100A6
biomarker
calumenin
cytohesin 2
systemic sclerosis
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
02 May 2021
02 May 2021
Historique:
received:
11
04
2021
revised:
29
04
2021
accepted:
30
04
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Systemic sclerosis (Ssc) is an autoimmune disease with incomplete known physiopathology. There is a high number of candidate proteomic biomarkers for Ssc that have not yet been confirmed on independent Ssc cohorts. The aim of the study was to confirm circulating S100A6, calumenin, and cytohesin 2 as biomarkers for Ssc. 53 Ssc patients and 26 age- and gender-matched controls were included. Serum S100A6, calumenin, and cytohesin 2 were evaluated with commercial ELISA kits. Associations between serum expression and clinical Ssc characteristics were evaluated. Serum calumenin, S100A6, and cytohesin 2 were higher in Ssc patients compared to controls. Calumenin associated with extensive cutaneous fibrosis, frequency of Raynaud phenomenon, and low complement level, and had a tendency to be higher in Ssc patients with pulmonary fibrosis. S100A6 correlated with the number of active digital ulcers. Serum cytohesin 2 levels were higher in patients with teleangiectasia and associated with pulmonary artery pressure. Serum calumenin, S100A6, and cytohesin 2 were confirmed as biomarkers on an independent group of Ssc patients. Calumenin had the best predictive capacity for cutaneous Ssc manifestations. Future studies are needed to evaluate the prognostic value of these biomarkers and evaluate them as possible therapeutic targets.
Sections du résumé
BACKGROUND
BACKGROUND
Systemic sclerosis (Ssc) is an autoimmune disease with incomplete known physiopathology. There is a high number of candidate proteomic biomarkers for Ssc that have not yet been confirmed on independent Ssc cohorts. The aim of the study was to confirm circulating S100A6, calumenin, and cytohesin 2 as biomarkers for Ssc.
METHODS
METHODS
53 Ssc patients and 26 age- and gender-matched controls were included. Serum S100A6, calumenin, and cytohesin 2 were evaluated with commercial ELISA kits. Associations between serum expression and clinical Ssc characteristics were evaluated.
RESULTS
RESULTS
Serum calumenin, S100A6, and cytohesin 2 were higher in Ssc patients compared to controls. Calumenin associated with extensive cutaneous fibrosis, frequency of Raynaud phenomenon, and low complement level, and had a tendency to be higher in Ssc patients with pulmonary fibrosis. S100A6 correlated with the number of active digital ulcers. Serum cytohesin 2 levels were higher in patients with teleangiectasia and associated with pulmonary artery pressure.
CONCLUSIONS
CONCLUSIONS
Serum calumenin, S100A6, and cytohesin 2 were confirmed as biomarkers on an independent group of Ssc patients. Calumenin had the best predictive capacity for cutaneous Ssc manifestations. Future studies are needed to evaluate the prognostic value of these biomarkers and evaluate them as possible therapeutic targets.
Identifiants
pubmed: 34063287
pii: jpm11050368
doi: 10.3390/jpm11050368
pmc: PMC8147492
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Romanian Ministry of Education and Research, CNCS - UEFISCDI
ID : PN-III-P1-1.1-PD-2019-0118
Références
Nat Rev Mol Cell Biol. 2011 Jun;12(6):362-75
pubmed: 21587297
J Cell Physiol. 2018 Oct;233(10):6344-6351
pubmed: 29665007
Mod Rheumatol. 2021 Jan;31(1):171-176
pubmed: 32013651
Eur Heart J. 2016 Jan 1;37(1):67-119
pubmed: 26320113
Biomarkers. 2014 Aug;19(5):345-55
pubmed: 24831309
Clin Lab. 2016;62(6):1109-16
pubmed: 27468573
J Dermatol. 2016 Jan;43(1):29-38
pubmed: 26782004
Nat Rev Rheumatol. 2011 Oct 25;8(1):42-54
pubmed: 22025123
Blood. 2004 Mar 15;103(6):2096-104
pubmed: 14630798
Biochim Biophys Acta. 2009 Jun;1793(6):993-1007
pubmed: 19121341
J Thromb Haemost. 2014 May;12(5):726-35
pubmed: 24581425
Proteomics Clin Appl. 2019 May;13(3):e1800181
pubmed: 30417587
Sci Rep. 2020 Feb 28;10(1):3672
pubmed: 32111889
Arthritis Res Ther. 2006;8(6):R160
pubmed: 17044913
J Clin Immunol. 2009 Mar;29(2):180-9
pubmed: 18825489
Antioxidants (Basel). 2021 Jan 09;10(1):
pubmed: 33435332
Proteomics. 2006 Jun;6(12):3509-19
pubmed: 16691550
Exp Cell Res. 1999 May 1;248(2):473-81
pubmed: 10222138
J Rheumatol. 1995 Jul;22(7):1281-5
pubmed: 7562759
Rheumatology (Oxford). 2010 Jul;49(7):1374-82
pubmed: 20400463
PLoS One. 2014 Mar 11;9(3):e90997
pubmed: 24618737
Rom J Intern Med. 2021 May 08;59(2):101-111
pubmed: 33565304
Transl Neurosci. 2021 Feb 03;12(1):67-75
pubmed: 33623713
Tumour Biol. 2018 Apr;40(4):1010428318767195
pubmed: 29629840
Ann Rheum Dis. 2003 Sep;62(9):904-5
pubmed: 12922969